Heparin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
oritavancin
Lipoglycopeptide · Antibacterial, Lipoglycopeptide, Cell Wall Synthesis Inhibitor, Membrane Disruptor
LipoglycopeptideAntibacterial, Lipoglycopeptide, Cell Wall Synthesis Inhibitor, Membrane Disruptor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
C
FDA category + note
Top interactionssee all 5 →
- HeparinSevereDatabaseDDInter
- LumateperoneSevereDatabaseDDInter
Mechanism
Oritavancin inhibits cell wall synthesis by binding to the d-alanyl-d-alanine terminus of cell wall precursor units, and also directly disrupts the bacterial membrane, leading to more rapid bactericidal activity than vancomycin. Lipoglycopeptides are able to dimerize and anchor their lipid moieties into the bacterial membrane, allowing for increased binding to the d-Ala-d-Ala target site and improved potency.
Indications
Complicated skin and soft tissue infections (SSTIs)Invasive staphylococcal infections (emerging data support)
Side effects
Common
HeadacheGastrointestinal distress
Serious
- Interference with coagulation tests (false elevations in INR, PT, aPTT)
- Cross-allergy with vancomycin possible
Pregnancy & lactation
Pregnancy
C
Drug interactions
Lumateperone
Severe
Database
Clinical effect not specified
Source: DDInter
Substrates Of Cyp2c19 And Cyp2c9
Moderate
Textbook
Decreased levels of interacting drug.
Avoid concomitant use if possible. If giving drugs concomitantly, monitor drug levels if possible.
Source: Harrison 22e · p1172
Substrates Of Cyp3a4 And Cyp2d6
Moderate
Textbook
Decreased levels of interacting drug.
Avoid concomitant use if possible. If giving drugs concomitantly, monitor drug levels if possible.
Source: Harrison 22e · p1172
Warfarin
Moderate
Database
Potential for altered anticoagulant effect of warfarin.
Should be used with warfarin only with careful monitoring.
Source: DDInter
7 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about oritavancin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team